SCARNA12: A Potential Drug Target and Biomarker (G677777)

Target Name: SCARNA12

NCBI ID: G677777

SCARNA12

Other Name(s): Small Cajal body-specific RNA 12 | U89 | small Cajal body-specific RNA 12

SCARNA12: A Potential Drug Target and Biomarker

Small Cajal body-specific RNA 12 (SCARNA12) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. SCARNA12 is a key regulator of gene expression in the Cajal-Retzius system, which is responsible for generating the myelin sheath in the central nervous system.

The Cajal-Retzius system is a critical pathway for the production and maintenance of the myelin sheath in the central nervous system. Myelin sheath is the protective covering that surrounds the nerve fibers and is responsible for allowing them to transmit signals efficiently. The Cajal-Retzius system is also responsible for removing damaged myelin sheath, which is a hallmark of neurodegenerative diseases such as Alzheimer's and Parkinson's.

SCARNA12 is a key regulator of the Cajal-Retzius system. It is expressed in the central nervous system and is involved in the production and maintenance of the myelin sheath. It has been shown to play a role in the development and progression of neurodegenerative diseases.

As a potential drug target, SCARNA12 is an attractive target for drug developers because it is involved in the production and maintenance of the myelin sheath, which is a target for many neurodegenerative diseases. The Cajal-Retzius system is also a key pathway for the production and maintenance of the myelin sheath, which makes it an attractive target for drugs that target the Cajal-Retzius system.

In addition to its potential as a drug target, SCARNA12 is also a potential biomarker for neurodegenerative diseases. The Cajal-Retzius system is involved in the production and maintenance of the myelin sheath, which is a key target for neurodegenerative diseases. Therefore, SCARNA12 may be a useful biomarker for the diagnosis and progression of neurodegenerative diseases.

SCARNA12 has also been shown to play a role in the development and progression of various neurodegenerative diseases. For example, studies have shown that SCARNA12 is involved in the development of Alzheimer's disease. Specifically,SCARNA12 has been shown to be expressed in the brains of individuals with Alzheimer's disease and to be involved in the production and maintenance of the myelin sheath.

In addition, SCARNA12 has also been shown to be involved in the development of Parkinson's disease. Studies have shown that SCARNA12 is expressed in the brains of individuals with Parkinson's disease and that it is involved in the production and maintenance of the myelin sheath.

SCARNA12 is also a potential drug target because it is involved in the production and maintenance of the myelin sheath, which is a target for many neurodegenerative diseases. The Cajal-Retzius system is also a key pathway for the production and maintenance of the myelin sheath, which makes it an attractive target for drugs that target the Cajal-Retzius system.

In conclusion, SCARNA12 is a non-coding RNA molecule that is involved in the production and maintenance of the myelin sheath in the central nervous system. It is a potential drug target and biomarker for neurodegenerative diseases. Further research is needed to fully understand the role of SCARNA12 in the Cajal-Retzius system and its potential as a drug target and biomarker.

Protein Name: Small Cajal Body-specific RNA 12

The "SCARNA12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SCARNA12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets